Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yan-Hua Zheng, Li Xu, Chun Cao, Juan Feng, Hai-Long Tang, Mi-Mi Shu, Guang-Xun Gao & Xie-Qun Chen. (2019) Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. OncoTargets and Therapy 12, pages 2751-2766.
Read now
Read now
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, Giulia Benevolo, Gloria Margiotta Casaluci, Marzia Varettoni, Claudia Baratè, Marina Motta, Guido Gini, Maria Cecilia Goldaniga, Carlo Visco, Francesco Zaja, Valeria Belsito Petrizi, Erika Ravelli, Massimo Gentile, Marina Aurora Urbano, Silvia Franceschetti, Paola Ghione, Lorella Orsucci, Anna Maria Frustaci, Gianluca Gaidano, Umberto Vitolo & Enrica Morra. (2015) Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leukemia & Lymphoma 56:9, pages 2637-2642.
Read now
Read now
Morie A. Gertz. (2010) Waldenström macroglobulinemia: is newer really better?. Leukemia & Lymphoma 51:12, pages 2152-2153.
Read now
Read now
Articles from other publishers (13)
Ali El-Ayoubi, James Q. Wang, Nadine Hein & Dipti Talaulikar. (2017) Role of plasma cells in Waldenstr?m macroglobulinaemia. Pathology 49:4, pages 337-345.
Crossref
Crossref
Dipti Talaulikar, Constantine S. Tam, Douglas Joshua, Joy Phoebe Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W. Roberts, Noemi Horvath, Cindy Lee, Andrew Zannettino, Ross Brown, Bradley Augustson, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Johnston, Judith Trotman, Akash Kalro, George Grigoriadis, Chris Ward & H. Miles Prince. (2017) Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal 47:1, pages 35-49.
Crossref
Crossref
A. Santos-Lozano, A. Morales-Gonzalez, F. Sanchis-Gomar, C. Cristi-Montero, C. Fiuza-Luces, H. Pareja-Galeano, J. Martínez-López, N. Garatachea & A. Lucia. (2016) Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. Critical Reviews in Oncology/Hematology 105, pages 118-126.
Crossref
Crossref
Xin Cao, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, Jatin Shan, Shaoying Li, Muzaffar Qazilbash, C. Cameron Yin, Donna Weber, Roberto N. Miranda, Zijun Y. Xu-Monette, L. Jeffrey Medeiros & Ken H. Young. (2015) Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Morie A. Gertz. (2015) Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology 90:4, pages 346-354.
Crossref
Crossref
Morie A. Gertz. (2013) Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology 88:8, pages 703-711.
Crossref
Crossref
Alessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, Giulia Benevolo, Marzia Varettoni, Marina Motta, Pietro Pioltelli, Guido Gini, Claudia Barate'Annamaria Luraschi, Eleonora Vismara, Anna Maria Frustaci, Michele Nichelatti, Umberto Vitolo, Luca Baldini & Enrica Morra. (2013) Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 13:2, pages 231-234.
Crossref
Crossref
Véronique LeblondSteve JohnsonSylvie ChevretAdrian CopplestoneSimon RuleOlivier TournilhacJohn Francis SeymourRussell D. PatmoreDavid WrightPierre MorelMarie-Sarah DilhuydySara WilloughbyCaroline DartigeasMarion MalphettesBruno RoyerMaeve EwingsGuy PrattJulie LejeuneFlorence Nguyen-KhacSylvain ChoquetRoger G. Owen. (2013) Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. Journal of Clinical Oncology 31:3, pages 301-307.
Crossref
Crossref
M. Hensel, J. Brust, C. Plöger, D. Schuster, M. L. Memmer, J. Franz-Werner, H.-P. Feustel, A. Karcher, S. Fuxius, F. A. Mosthaf, M. Rieger, A. D. Ho & M. Witzens-Harig. (2012) Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital. Annals of Hematology 91:12, pages 1923-1928.
Crossref
Crossref
Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, Giuseppe Rossi, Umberto Vitolo, Alessandra Tedeschi, Francesco Merli, Luigi Rigacci, Caterina Stelitano, Maria Goldaniga, Donato Mannina, Pellegrino Musto, Francesca Rossi, Enrica Gamba & Luca Baldini. (2011) Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B‐cell nonfollicular lymphomas. Cancer 118:16, pages 3954-3961.
Crossref
Crossref
Morie A. Gertz. (2012) Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology 87:5, pages 503-510.
Crossref
Crossref
Junji Koya, Atsushi Iwata, Fumihiko Nakamura, Yu Nagashima, Motoshi Ichikawa, Shoji Tsuji & Mineo Kurokawa. (2012) Fludarabine may overcome resistance to rituximab in IgM-related neuropathy. Journal of the Neurological Sciences 315:1-2, pages 150-152.
Crossref
Crossref
Morie A. Gertz. (2011) Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology 86:5, pages 411-416.
Crossref
Crossref